Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Multivariate and univariate analysis of body weight at 3 and 9 months demonstrated no significant difference between groups (Supplementary Table 6.1, Supplementary Table 6.3, Table 2)
Canakinumab: a human anti-IL-1beta monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes
Lean mass loss is clinically relevant because it reduces physical function and resting metabolic rate, potentially amplifying compensatory responses and increasing susceptibility to weight regain ( GLP-1RAs are not designed to exert anabolic effects on skeletal muscle
doi: 10.1038/s41577-019-0139-2 66 KongRWangNHanWBaoWLuJ
*Correspondence: Sameer A
Retrieved May 27, 2025, from National Library of Medicine
US$ 22.63
US$ 26.39
US$ 20.42
US$ 21.13
US$ 25.85
US$ 20.56
